B30.2/SPRY domain in tripartite motif-containing 22 is essential for the formation of distinct nuclear bodies

FEBS Letters

Volumn 583, Issue 12, 2009, Pages 2093-2099

  Sivaramakrishnan, Gayathri ^a   Sun, Yang ^a   Rajmohan, Rajamuthiah ^a   Lin, Valerie C L ^a  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

B30.2 SplA and ryanodine receptor; Nuclear body; Nuclear localization; Tripartite motif containing 22

Indexed keywords

ALANINE; CELL PROTEIN; CYSTEINE; RYANODINE RECEPTOR; TRIPARTITE MOTIF PROTEIN 22; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS INCLUSION BODY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN LOCALIZATION; RING FINGER MOTIF;

AMINO ACID SEQUENCE; CELL LINE; CELL NUCLEUS; CYSTEINE; HUMANS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NUCLEAR LOCALIZATION SIGNALS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; SEQUENCE DELETION; TRANSFECTION;

EID: 67349120542     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.05.036     Document Type: Article

References (40)

1. Reymond A., Meroni G., Fantozzi A., Merla G., Cairo S., Luzi L., Riganelli D., Zanaria E., Messali S., Cainarca S., Guffanti A., Minucci S., Pelicci P.G., and Ballabio A. The tripartite motif family identifies cell compartments. EMBO J. 20 (2001) 2140-2151
2. Duan Z., Gao B., Xu W., and Xiong S. Identification of TRIM22 as a RING finger E3 ubiquitin ligase. Biochem. Biophys. Res. Commun. 374 (2008) 502-506
3. Gack M.U., Shin Y.C., Joo C.H., Urano T., Liang C., Sun L., Takeuchi O., Akira S., Chen Z., Inoue S., and Jung J.U. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446 (2007) 916-920
4. Trockenbacher A., Suckow V., Foerster J., Winter J., Krauss S., Ropers H.H., Schneider R., and Schweiger S. MID1, mutated in Opitz syndrome, encodes an ubiquitin ligase that targets phosphatase 2A for degradation. Nat. Genet. 29 (2001) 287-294
5. Urano T., Saito T., Tsukui T., Fujita M., Hosoi T., Muramatsu M., Ouchi Y., and Inoue S. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417 (2002) 871-875
6. Yamauchi K., Wada K., Tanji K., Tanaka M., and Kamitani T. Ubiquitination of E3 ubiquitin ligase TRIM5alpha and its potential role. FEBS J. 275 (2008) 1540-1555
7. Borden K.L., Lally J.M., Martin S.R., O'Reilly N.J., Solomon E., and Freemont P.S. In vivo and in vitro characterization of the B1 and B2 zinc-binding domains from the acute promyelocytic leukemia protooncoprotein PML. Proc. Natl. Acad. Sci. USA 93 (1996) 1601-1606
8. Cao T., Borden K.L., Freemont P.S., and Etkin L.D. Involvement of the rfp tripartite motif in protein-protein interactions and subcellular distribution. J. Cell Sci. 110 (1997) 1563-1571
9. Cainarca S., Messali S., Ballabio A., and Meroni G. Functional characterization of the Opitz syndrome gene product (midin): evidence for homodimerization and association with microtubules throughout the cell cycle. Human Mol. Genet. 8 (1999) 1387-1396
10. Ohkura S., Yap M.W., Sheldon T., and Stoye J.P. All three variable regions of the TRIM5alpha B30.2 domain can contribute to the specificity of retrovirus restriction. J. Virol. 80 (2006) 8554-8565
11. Rhodes D.A., and Trowsdale J. TRIM21 is a trimeric protein that binds IgG Fc via the B30.2 domain. Mol. Immunol. 44 (2007) 2406-2414
12. Woo J.S., Imm J.H., Min C.K., Kim K.J., Cha S.S., and Oh B.H. Structural and functional insights into the B30.2/SPRY domain. EMBO J. 25 (2006) 1353-1363
13. Beenders B., Jones P.L., and Bellini M. The tripartite motif of nuclear factor 7 is required for its association with transcriptional units. Mol. Cell Biol. 27 (2007) 2615-2624
14. Javanbakht H., Yuan W., Yeung D.F., Song B., Diaz-Griffero F., Li Y., Li X., Stremlau M., and Sodroski J. Characterization of TRIM5alpha trimerization and its contribution to human immunodeficiency virus capsid binding. Virology 353 (2006) 234-246
15. Izmailova E., Bertley F.M., Huang Q., Makori N., Miller C.J., Young R.A., and Aldovini A. HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat. Med. 9 (2003) 191-197
16. Obad S., Brunnstrom H., Vallon-Christersson J., Borg A., Drott K., and Gullberg U. Staf50 is a novel p53 target gene conferring reduced clonogenic growth of leukemic U-937 cells. Oncogene 23 (2004) 4050-4059
17. Zhang J., Das S.C., Kotalik C., Pattnaik A.K., and Zhang L. The latent membrane protein 1 of Epstein-Barr virus establishes an antiviral state via induction of interferon-stimulated genes. J. Biol. Chem. 279 (2004) 46335-46342
18. Tissot C., and Mechti N. Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J. Biol. Chem. 270 (1995) 14891-14898
19. Barr S.D., Smiley J.R., and Bushman F.D. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog. 4 (2008) e1000007
20. Bernardi R., and Pandolfi P.P. Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat. Rev. Mol. Cell Biol. 8 (2007) 1006-1016
21. Cioce M., and Lamond A.I. Cajal bodies: a long history of discovery. Ann. Rev. Cell Dev. Biol. 21 (2005) 105-131
22. Kastner P., Perez A., Lutz Y., Rochette-Egly C., Gaub M.P., Durand B., Lanotte M., Berger R., and Chambon P. Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. EMBO J. 11 (1992) 629-642
23. Rowley J.D., Golomb H.M., Vardiman J., Fukuhara S., Dougherty C., and Potter D. Further evidence for a non-random chromosomal abnormality in acute promyelocytic leukemia. Int. J. Cancer 20 (1977) 869-872
24. Mu Z.M., Chin K.V., Liu J.H., Lozano G., and Chang K.S. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol. Cell Biol. 14 (1994) 6858-6867
25. Grobelny J.V., Godwin A.K., and Broccoli D. ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. J. Cell Sci. 113 (2000) 4577-4585
26. Everett R.D., and Chelbi-Alix M.K. PML and PML nuclear bodies: implications in antiviral defence. Biochimie 89 (2007) 819-830
27. Sivaramakrishnan G., Sun Y., Tan S.K., and Lin V.C.L. Dynamic localization of tripartite motif-containing 22 in nuclear and nucleolar bodies. Exp. Cell Res. 315 (2009) 1521-1532
28. Manser E., Huang H.Y., Loo T.H., Chen X.Q., Dong J.M., Leung T., and Lim L. Expression of constitutively active alpha-PAK reveals effects of the kinase on actin and focal complexes. Mol. Cell Biol. 17 (1997) 1129-1143
29. Zheng Z.Y., Bay B.H., Aw S.E., and Lin V.C. A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells. J. Biol. Chem. 280 (2005) 17480-17487
30. Lorick K.L., Jensen J.P., Fang S., Ong A.M., Hatakeyama S., and Weissman A.M. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl. Acad. Sci. USA 96 (1999) 11364-11369
31. Boddy M.N., Duprez E., Borden K.L., and Freemont P.S. Surface residue mutations of the PML RING finger domain alter the formation of nuclear matrix-associated PML bodies. J. Cell Sci. 110 (1997) 2197-2205
32. Borden K.L., Boddy M.N., Lally J., O'Reilly N.J., Martin S., Howe K., Solomon E., and Freemont P.S. The solution structure of the RING finger domain from the acute promyelocytic leukaemia proto-oncoprotein PML. EMBO J. 14 (1995) 1532-1541
33. Borden K.L., Campbell-Dwyer E.J., and Salvato M.S. The promyelocytic leukemia protein PML has a pro-apoptotic activity mediated through its RING domain. FEBS Lett. 418 (1997) 30-34
34. Fagioli M., Alcalay M., Tomassoni L., Ferrucci P.F., Mencarelli A., Riganelli D., Grignani F., Pozzan T., Nicoletti I., and Pelicci P.G. Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. Oncogene 16 (1998) 2905-2913
35. Wang R., and Brattain M.G. The maximal size of protein to diffuse through the nuclear pore is larger than 60 kDa. FEBS Lett. 581 (2007) 3164-3170
36. Dingwall C., and Laskey R.A. Nuclear targeting sequences - a consensus?. Trends Biochem. Sci. 16 (1991) 478-481
37. Qin Q., Inatome R., Hotta A., Kojima M., Yamamura H., Hirai H., Yoshizawa T., Tanaka H., Fukami K., and Yanagi S. A novel GTPase, CRAG, mediates promyelocytic leukemia protein-associated nuclear body formation and degradation of expanded polyglutamine protein. J. Cell Biol. 172 (2006) 497-504
38. Bohmann K., Ferreira J.A., and Lamond A.I. Mutational analysis of p80 coilin indicates a functional interaction between coiled bodies and the nucleolus. J. Cell Biol. 131 (1995) 817-831
39. Sawyer S.L., Wu L.I., Emerman M., and Malik H.S. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. USA 102 (2005) 2832-2837
40. Schweiger S., Foerster J., Lehmann T., Suckow V., Muller Y.A., Walter G., Davies T., Porter H., van Bokhoven H., Lunt P.W., Traub P., and Ropers H.H. The Opitz syndrome gene product, MID1, associates with microtubules. Proc. Natl. Acad. Sci. USA 96 (1999) 2794-2799